Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Abstract Background The objective of the IMPROVE study was patients’ preference for either endocrine-based therapy or combined chemo- and anti-angiogenic therapy in advanced HR-positive/HER2-negative breast cancer. Methods In this randomized, cross-over phase IV study, 77 patients were recruited in...

Full description

Bibliographic Details
Main Authors: Thomas Decker, Ulrike Söling, Antje Hahn, Christoph Maintz, Christian Martin Kurbacher, Ursula Vehling-Kaiser, Dagmar Sent, Peter Klare, Volker Hagen, Marco Chiabudini, Julia Falkenstein, Martin Indorf, Eva Runkel, Karin Potthoff
Format: Article
Language:English
Published: BMC 2020-04-01
Series:BMC Cancer
Subjects:
Advanced breast Cancer
Endocrine therapy
Combined chemo- and anti-Angiogenic therapy
Patient preference
Randomized, cross-over phase IV study
Online Access:http://link.springer.com/article/10.1186/s12885-020-06747-y

Internet

http://link.springer.com/article/10.1186/s12885-020-06747-y

Similar Items